The effect of acyclovir on the tubular secretion of creatinine in vitro
© Gunness et al; licensee BioMed Central Ltd. 2010
Received: 13 August 2010
Accepted: 30 December 2010
Published: 30 December 2010
While generally well tolerated, severe nephrotoxicity has been observed in some children receiving acyclovir. A pronounced elevation in plasma creatinine in the absence of other clinical manifestations of overt nephrotoxicity has been frequently documented. Several drugs have been shown to increase plasma creatinine by inhibiting its renal tubular secretion rather than by decreasing glomerular filtration rate (GFR). Creatinine and acyclovir may be transported by similar tubular transport mechanisms, thus, it is plausible that in some cases, the observed increase in plasma creatinine may be partially due to inhibition of tubular secretion of creatinine, and not solely due to decreased GFR. Our objective was to determine whether acyclovir inhibits the tubular secretion of creatinine.
Porcine (LLC-PK1) and human (HK-2) renal proximal tubular cell monolayers cultured on microporous membrane filters were exposed to [2-14C] creatinine (5 μM) in the absence or presence of quinidine (1E+03 μM), cimetidine (1E+03 μM) or acyclovir (22 - 89 μM) in incubation medium.
Results illustrated that in evident contrast to quinidine, acyclovir did not inhibit creatinine transport in LLC-PK1 and HK-2 cell monolayers.
The results suggest that acyclovir does not affect the renal tubular handling of creatinine, and hence, the pronounced, transient increase in plasma creatinine is due to decreased GFR, and not to a spurious increase in plasma creatinine.
Acyclovir is an antiviral agent that is commonly used to treat severe viral infections including herpes simplex and varicella zoster, in children . Acyclovir is generally well tolerated , however, in some cases, severe nephrotoxicity has been reported [2–8]. Acyclovir - induced nephrotoxicity is typically evidenced by elevated plasma creatinine and urea levels, the occurrence of abnormal urine sediments or acute renal failure [2–5, 7, 8].
Crystalluria leading to obstructive nephropathy is widely believed to be the mechanism of acyclovir - induced nephrotoxicity . However, there are several documented cases of acyclovir - induced nephrotoxicity in the absence of crystalluria [7, 8, 10]; suggesting that acyclovir induces direct insult to tubular cells. Recently, we provided the first in vitro experimental evidence which supports existing clinical evidence of direct renal tubular damage induced by acyclovir .
Cases of elevated plasma creatinine levels in children who received intravenous acyclovir
Magnitude of increase in plasma creatinine
Relevant clinical details
5 fold increase within 2 days
Creatinine returned to normal in 4 days
No other pathology reported
No further impairment reported
4 fold increase within 4 days
Mild reduction in urine output
Creatinine returned to normal 1 week following acyclovir discontinuation
2 fold increase within 6 days
Creatinine continued to increase following acyclovir discontinuation. Creatinine returned to normal within 1 week
9 fold increase within 2 to 3 days
Urinary α1-microglobulin and albumin
Creatinine returned to normal in 3 - 9 days
3 fold increase within 4 days
No other information provided
Creatinine, a commonly used biomarker that is used to assess renal function, is eliminated by the kidney via both glomerular filtration and tubular secretion . The mechanisms underlying the renal tubular transport of creatinine has not been fully elucidated. As explained by Urakami and colleagues , both acid and base secreting mechanisms may play a role in the renal tubular transport of creatinine [13–15, 17–22, 25–27]. Hence, some drugs may share similar renal tubular transport mechanisms with creatinine. Drugs that share transport mechanisms with creatinine may compete with it for tubular transport, and subsequently inhibit creatinine secretion to result in a ungenuine elevation of plasma creatinine that may not be due to decreased glomerular filtrate rate (GFR). Cimetidine [12–16], trimethoprim [17–19], pyrimethamine , dronedarone  and salicylates  are examples of drugs that share similar renal tubular transport mechanisms with creatinine and induce spurious increases in plasma creatinine by competing with and subsequently inhibiting its secretion.
Similar to creatinine, both acid and base secreting pathways may be involved in the renal tubular transport of acyclovir . Additionally, it is likely that creatinine [24–26] and acyclovir  may be transported by similar organic anion transporters (OAT) and organic cation transporters (OCT). Therefore, it is plausible that acyclovir may compete with and successively inhibit renal secretion of creatinine, resulting in elevations in plasma creatinine that may be disproportional to the degree of renal dysfunction.
Employing plasma creatinine levels to estimate GFR, results from previous studies [29, 30] have illustrated that acyclovir - induced nephrotoxicity induces a significant reduction in GFR in children. However, based on: (1) the cases presented in Table 1, (2) the awareness that several non-nephrotoxic drugs are known to induce transient increases in plasma creatinine [12–22] and (3) the knowledge that acyclovir and creatinine may share similar renal tubular transport mechanisms; we hypothesized that the pronounced, transient increase in plasma creatinine levels observed in some patients may be partially due to the inhibition of renal tubular secretion of creatinine by acyclovir, and not entirely the result of decreased GFR. To the best of our knowledge, the effect of acyclovir on the renal tubular secretion of creatinine in vitro has not been previously evaluated. Thus, the objective of the study was to determine whether acyclovir inhibits the renal tubular secretion of creatinine. It is important to determine whether acyclovir inhibits the tubular transport of creatinine, because if this is the case, then in addition to creatinine, other biomarkers should always be employed to assess renal function in patients receiving acyclovir treatment.
In the present study we were specifically interested in determining the possible interaction between creatinine and acyclovir during renal tubular transport by the OCT pathway. The porcine renal tubular cell line, LLC-PK1, has been used as an in vitro renal tubular model in a vast array of transepithelial transport studies. Furthermore, the LLC-PK1 cells are an appropriate in vitro model for specifically studying renal tubular transport of organic cations because they are known to possess functional OCTs [31–33]. However, although the LLC-PK1 cells retain similar physiological and biochemical properties compared to human renal proximal tubular cells , interspecies differences in drug disposition exists [35–37]. Hence, the use of a human renal proximal tubular cell line, such as the HK-2 cell line, would be a more suitable in vitro model to study the mechanisms of renal tubular drug transport in humans. Porcine LLC-PK1 and human HK-2 cells were employed in our transepithelial transport studies.
The LLC-PK1 cells (American Type Culture Collection (ATCC), USA) were cultured in growth medium which consisted of Minimum Essential Medium (MEM) alpha modified (Fisher Scientific, Canada), supplemented with 2 mM L-glutamine, 100 units/mL penicillin, 100 μg streptomycin and 10% (v/v) fetal bovine serum (Invitrogen Canada Inc., Canada). The HK-2 cells (ATCC) were cultured in growth medium which consisted of Keratinocyte-Serum Free Medium, supplemented with human recombinant epidermal growth factor 1-53 (5 ng/mL) and bovine pituitary extract (0.05 mg/mL) (Invitrogen Canada Inc.) The LLC-PK1 and HK-2 cells were maintained at 37°C in a sterile, humidified atmosphere of 5% CO2 and 95% O2.
Transepithelial transport studies
The transepithelial transport studies were conducted as outlined by Urakami et al.  with modifications. The LLC-PK1 and HK-2 cells were seeded at densities of 4.5E+05 cells/0.9 cm2 and 5.0E+05 cells/0.9 cm2, respectively, on microporous membrane filter inserts (3 μm pore size, 0.9 cm2 growth area) that were placed inside cell culture chambers (VWR International, Canada). A consistent (1 mL) volume of growth or incubation medium (containing no substrates, radiolabeled or non-radiolabeled substrates) was placed in the apical and basolateral compartments of the cell culture chambers during culturing of the cells or during all transport experiments. The LLC-PK1 and HK-2 cell monolayers used for transport studies were cultured in growth medium for 6 and 3 days, respectively, after seeding. All transepithelial transport studies were conducted on confluent cell monolayers.
At the time of commencement of the transport experiments, the growth medium from the cell culture chamber was removed and both sides of the cell monolayers were washed twice with incubation medium (145 mM NaCl, 3 mM KCl, 1 mM CaCl2, 0.5 mM MgCl2, 5 mM D-glucose and 5 mM HEPES (pH 7.4)). Incubation medium was used for all transport experiments. Cell monolayers were incubated with medium for 10 minutes. Following the 10 minute incubation period, the medium was removed and the cell monolayers were incubated with medium as follows: the medium added to the basolateral compartment of the cell culture chamber contained respective radiolabeled and non-radiolabeled substrates and the medium added to the apical compartment of the cell culture chamber contained neither radiolabeled nor non-radiolabeled substrates. The radiolabeled and non-radiolabeled substrates used in the transport studies are outlined below.
The transepithelial transport (basolateral-to-apical) of radiolabeled substrates across the cell monolayers was assessed at specific intervals (LLC-PK1: 0, 15, 30, 45 and 60 minutes; HK-2: 0, 7.5, 15, 22.5 and 30 minutes) over 60 and 30 minutes, respectively. Studies were conducted over different duration of times in LLC-PK1 and HK-2 cells due to differences in the integrity of the cell monolayers. The paracellular flux (basolateral-to-apical) of D-[1-3H(N)] mannitol (PerkinElmer, Canada) across the cell monolayers was used to assess the integrity of cell monolayers. A priori decision was made to eliminate the results from any cell monolayers where the paracellular flux of D-[1-3H(N)] mannitol across LLC-PK1 or HK-2 cell monolayers was greater than 5% over the respective experimental period.
The transport of radiolabeled substrates was assessed by measuring the radioactivity of 50 μL aliquots of medium that were sampled from the apical and basolateral compartments of the cell culture chamber, at the aforementioned specified time intervals for the respective cell line. Radioactivity was measured as disintegrations per minutes (DPM) using a LS 6500 liquid scintillation (Beckman Coulter Canada Inc., Canada).
Tetraethylammonium (TEA) transport across cell monolayers
In order to determine whether the LLC-PK1 and HK-2 cells used in the present studies possessed functional organic cation transporters; TEA transport across cell monolayers was assessed. The TEA is a classical organic cation substrate for OCTs [31, 32, 38]. The transport of TEA across LLC-PK1 and HK-2 cell monolayers was assessed in the presence and absence of the known inhibitor of organic cation transport [24, 31–33], quinidine (Sigma-Aldrich Canada Ltd., Canada). Cell monolayers were incubated with medium (containing [ethyl-1-14C] TEA (5 μM) (American Radiolabeled Chemicals Inc., USA) in the presence or absence of quinidine (1E+03 μM). The transport of TEA was assessed as described above.
Acyclovir transport across cell monolayers
The transport of acyclovir across LLC-PK1 or HK-2 cell monolayers was assessed in the presence or absence of quinidine. Cell monolayers were incubated with medium (containing [8-14C] acyclovir (5E-05 μM) (American Radiolabeled Chemicals Inc.)) in the presence or absence of quinidine (1E+03 μM). The transport of acyclovir was assessed as described above.
The effect of acyclovir on creatinine transport across cell monolayers
The transport of creatinine was assessed across LLC-PK1 or HK-2 cell monolayers in the presence or absence of acyclovir. Cell monolayers were incubated with medium (containing [2-14C] creatinine (5 μM) (American Radiolabeled Chemicals Inc.)) in the presence or absence of quinidine (1E+03 μM), cimetidine (1E+03 μM) (Sigma-Aldrich Canada Ltd.) or acyclovir (22 to 89 μM) (Pharmacy at the Hospital for Sick Children, Canada). The acyclovir concentrations used in the experiments are representative of concentrations of acyclovir that are found in the plasma and hence, are the concentrations which creatinine may encounter in plasma.
Statistical analyses were performed using ANOVA followed by Tukey's HSD post hoc tests. Statistical analyses were performed on substrate radioactivity (DPM) data. Data are presented as the mean ± standard error (SE) from 3 cell monolayer experiments. Data were considered statistically significant if p < 0.05.
TEA transport across LLC-PK1 and HK-2 cell monolayers
Acyclovir transport across LLC-PK1 and HK-2 cell monolayers
The effect of acyclovir on creatinine transport across LLC-PK1 and HK-2 cell monolayers
The objective of our study was to determine whether acyclovir inhibits creatinine transport. The LLC-PK1 and HK-2 cell lines were employed as our in vitro models. The results suggest that LLC-PK1 (Figure 1) and HK-2 (Figure 2) cells possess functional OCTs, thereby making them appropriate models to study the renal tubular transport of organic cations such as creatinine and acyclovir. In contrast to LLC-PK1 cells, the presence of functional OCTs in HK-2 cells has not been previously reported. Hence, our study is the first to report that HK-2 cells possess functional OCTs, thereby making them an invaluable in vitro model to study the renal tubular transport of organic cations in humans.
Importantly, in contrast to quinidine (LLC-PK1 and HK-2) (Figures 5 and 6) or cimetidine (LLC-PK1) (Figure 5), acyclovir did not inhibit creatinine transport across both types of cell monolayers; suggesting that acyclovir does not affect the renal tubular handling of creatinine. As previously explained; (1) the marked, transient increase in plasma creatinine observed in some patients who received acyclovir (Table 1) is similar to that observed in some patients who received non-nephrotoxic drugs that share similar renal tubular transport with creatinine and hence compete with and subsequently inhibit creatinine secretion [12–22] and (2) acyclovir may share similar renal tubular transport mechanisms with creatinine [24–26, 28]. Hence, if this is the case, it is possible that our results illustrate that acyclovir did not inhibit the tubular transport of creatinine for the following reasons:
First, as reviewed by Andreev et al. , some drugs, such as phenacemide and vitamin D derivatives induce a marked, transient increase in plasma creatinine in the absence of other significant signs of renal impairment by other less well understood mechanisms, including interference with the Jaffé-based assay for creatinine measurement and modification of the production rate and release of creatinine, respectively. Thus, acyclovir may affect plasma creatinine levels by a yet unknown mechanism(s).
Second, based on our results, it can be argued that acyclovir did not inhibit creatinine transport across LLC-PK1 cell monolayers because in contrast to creatinine (Figure 5), the OCT pathway in the LLC-PK1 cells did not appear to play a significant role in acyclovir transport (Figure 3), and hence acyclovir was unlikely to compete with and subsequently inhibit creatinine transport via the OCT pathway present in the cells. Furthermore interspecies differences in drug disposition[35, 36] and protein expression  for instance, may provide an explanation for the lack of inhibition of creatinine transport by acyclovir in LLC-PK1 cells. For example, the degree of amino acid sequence similarity between porcine OCT1 (pOCT1) and hOCT1 is approximately 78% , while porcine OCT2 (pOCT2) and hOCT2 share approximately 86% amino acid sequence homology .
However, in contrast to the results obtained in LLC-PK1 cells, the OCT pathway in human HK-2 cells played a significant role in both acyclovir (Figure 4) and creatinine transport (Figure 6), yet similar to the results obtained in LLC-PK1 cells, acyclovir did not inhibit creatinine transport in human HK-2 cells. The results from previous studies suggest that the OCTs may mediate the renal tubular transport of both creatinine [24, 25] and acyclovir . However, while OCT2 appears to be primarily responsible for creatinine transport [24, 25], it appears that OCT1 may be predominantly accountable for acyclovir transport . Reviewed by Dresser et al. , OCT1 and OCT2 are both located in the human kidney, therefore it is possible that renal secretion of creatinine and acyclovir may be mediated by different OCTs; OCT2 and OCT1, respectively. Thus, acyclovir may not impede creatinine tubular transport in vitro and possibly in vivo, in humans as well.
The knowledge that OCT1, rather than OCT2, mediate acyclovir transport may also provide an explanation for the insignificant transport of acyclovir across LLC-PK1 cells (Figure 3). In contrast to OCT2 , OCT1 has not been specifically identified in LLC-PK1 cells. The LLC-PK1 cells may lack or have reduced expression of OCT1. Therefore, LLC-PK1 cells may be unable to transport acyclovir via their existing OCT system, and hence may be an inappropriate model to examine acyclovir transport via the same. Furthermore, if the plausible lack of or reduced OCT1 expression in LLC-PK1 cells resulted in the absence of significant acyclovir transport across the cell monolayers (Figure 3), then the results provide additional support for the postulation that acyclovir and creatinine may be transported via different OCTs.
Third, we employed in vitro models in our studies. Although in vitro models are widely used in pharmacology and toxicology studies to address questions at both the cellular and molecular level, there are several major disadvantages of in vitro models that limit their ability to accurately predict responses in vivo[37, 45]. Major disadvantages include disruption of cellular structural integrity and intercellular relationships, the production of artifactual drug binding sites that does not normally exist in vivo, differences between in vitro and in vivo drug pharmacokinetics and altered protein expression . Therefore, the transport of creatinine and/or acyclovir in vitro may be altered from its transport in vivo, in humans.
In our study, we investigated the possible interaction between creatinine and acyclovir at the OCT pathway. However, it is also possible that the interaction between creatinine and acyclovir may be occurring at the OAT pathway, rather than at the OCT pathway. Results from studies suggest that the OAT system may play a fundamental role in both creatinine [22, 26, 27] and acyclovir  transport. The LLC-PK1 cells do not possess OATs [46, 47], and therefore are an inappropriate in vitro model to study the possible interaction between creatinine and acyclovir at the OAT pathway. The expression of functional OATs in HK-2 cells is currently unknown and we did not determine the same in our study. However, if functional OATs are expressed in HK-2 cells, and both creatinine and acyclovir were significantly transported by the same OAT(s), then, in the presence of acyclovir, decreased creatinine transport across the cell monolayers would have likely been observed. Alternatively, as suggested for OCTs, creatinine and acyclovir may have been transported by different OATs expressed in the HK-2 cells, such that acyclovir did not hinder creatinine transport via the OAT pathway.
Engaging both animal (LLC-PK1) and human (HK-2) cell models, we illustrated that acyclovir did not inhibit creatinine transport. Taken together, the results suggest that acyclovir does not affect the renal tubular transport of creatinine, in vitro and possibly, in vivo, in humans as well. Therefore, the pronounced, transient elevation in plasma creatinine observed in some children may be solely due to decreased GFR as a result of renal dysfunction induced by acyclovir, and not due to a spurious acyclovir-creatinine interaction on the tubular level.
The study was supported by the grant from the Canadian Institutes of Health Research (CIHR).
- Bryson YJ: The use of acyclovir in children. Pediatr Infect Dis. 1984, 3: 345-348. 10.1097/00006454-198407000-00017.PubMedView ArticleGoogle Scholar
- Keeney RE, Kirk LE, Bridgen D: Acyclovir tolerance in humans. Am J Med. 1982, 73: 176-181. 10.1016/0002-9343(82)90086-9.PubMedView ArticleGoogle Scholar
- Bianchetti MG, Roduit C, Oetliker OH: Acyclovir-induced renal failure: course and risk factors. Pediatr Nephrol. 1991, 5: 238-239. 10.1007/BF01095963.PubMedView ArticleGoogle Scholar
- Brigden D, Rosling AE, Woods NC: Renal function after acyclovir intravenous injection. Am J Med. 1982, 73: 182-185. 10.1016/0002-9343(82)90087-0.PubMedView ArticleGoogle Scholar
- Chou JW, Yong C, Wootton SH: Case 2: Rash, fever and headache....first, do no harm. Paediatr Child Health. 2008, 13: 49-52.PubMedPubMed CentralGoogle Scholar
- Potter JL, Krill CE: Acyclovir crystalluria. Pediatr Infect Dis. 1986, 5: 710-712. 10.1097/00006454-198611000-00027.PubMedView ArticleGoogle Scholar
- Vachvanichsanong P, Patamasucon P, Malagon M, Moore ES: Acute renal failure in a child associated with acyclovir. Pediatr Nephrol. 1995, 9: 346-347. 10.1007/BF02254206.PubMedView ArticleGoogle Scholar
- Vomiero G, Carpenter B, Robb I, Filler G: Combination of ceftriaxone and acyclovir - an underestimated nephrotoxic potential?. Pediatr Nephrol. 2002, 17: 633-637. 10.1007/s00467-002-0867-5.PubMedView ArticleGoogle Scholar
- Sawyer MH, Webb DE, Balow JE, Straus SE: Acyclovir-induced renal failure. Clinical course and histology. Am J Med. 1988, 84: 1067-1071. 10.1016/0002-9343(88)90313-0.PubMedView ArticleGoogle Scholar
- Ahmad T, Simmonds M, McIver AG, McGraw ME: Reversible renal failure in renal transplant patients receiving oral acyclovir prophylaxis. Pediatr Nephrol. 1994, 8: 489-491. 10.1007/BF00856544.PubMedView ArticleGoogle Scholar
- Gunness P, Aleksa K, Kousage K, Ito S, Koren G: Comparison of the novel HK-2 human renal proximal tubular cell line to the standard LLC-PK1 cell line in studying drug-induced nephrotoxicity. Can J Physiol Pharmacol. 2010, 88: 448-455. 10.1139/Y10-023.PubMedView ArticleGoogle Scholar
- Blackwood WS, Maudgal DP, Pickard RG, Lawrence D, Northfield TC: Cimetidine in duodenal ulcer. Controlled trial. Lancet. 1976, 2: 174-176. 10.1016/S0140-6736(76)92347-3.PubMedView ArticleGoogle Scholar
- Burgess E, Blair A, Krichman K, Cutler RE: Inhibition of renal creatinine secretion by cimetidine in humans. Ren Physiol. 1982, 5: 27-30.PubMedGoogle Scholar
- Dubb JW, Stote RM, Familiar RG, Lee K, Alexander F: Effect of cimetidine on renal function in normal man. Clin Pharmacol Ther. 1978, 24: 76-83.PubMedView ArticleGoogle Scholar
- Dutt MK, Moody P, Northfield TC: Effect of cimetidine on renal function in man. Br J Clin Pharmacol. 1981, 12: 47-50.PubMedPubMed CentralView ArticleGoogle Scholar
- Haggie SJ, Fermont DC, Wyllie JH: Treatment of duodenal ulcer with cimetidine. Lancet. 1976, 1: 983-984. 10.1016/S0140-6736(76)91859-6.PubMedView ArticleGoogle Scholar
- Berglund F, Killander J, Pompeius R: Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine in man. J Urol. 1975, 114: 802-808.PubMedGoogle Scholar
- Kastrup J, Petersen P, Bartram R, Hansen JM: The effect of trimethoprim on serum creatinine. Br J Urol. 1985, 57: 265-268. 10.1111/j.1464-410X.1985.tb06340.x.PubMedView ArticleGoogle Scholar
- Myre SA, McCann J, First MR, Cluxton RJ: Effect of trimethoprim on serum creatinine in healthy and chronic renal failure volunteers. Ther Drug Monit. 1987, 9: 161-165. 10.1097/00007691-198706000-00006.PubMedView ArticleGoogle Scholar
- Opravil M, Keusch G, Luthy R: Pyrimethamine inhibits renal secretion of creatinine. Antimicrob Agents Chemother. 1993, 37: 1056-1060.PubMedPubMed CentralView ArticleGoogle Scholar
- Tschuppert Y, Buclin T, Rothuizen LE, Decosterd LA, Galleyrand J, Gaud C, Biollaz J: Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol. 2007, 64: 785-791.PubMedPubMed CentralGoogle Scholar
- Burry HC, Dieppe PA: Apparent reduction of endogenous creatinine clearance by salicylate treatment. Br Med J. 1976, 2: 16-17. 10.1136/bmj.2.6026.16.PubMedPubMed CentralView ArticleGoogle Scholar
- Toto RD: Conventional measurement of renal function utilizing serum creatinine, creatinine clearance, inulin and para-aminohippuric acid clearance. Curr Opin Nephrol Hypertens. 1995, 4: 505-509. 10.1097/00041552-199511000-00009.PubMedView ArticleGoogle Scholar
- Urakami Y, Kimura N, Okuda M, Inui K: Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res. 2004, 21: 976-981. 10.1023/B:PHAM.0000029286.45788.ad.PubMedView ArticleGoogle Scholar
- Okuda M, Kimura N, Inui K: Interactions of fluoroquinolone antibacterials, DX-619 and levofloxacin, with creatinine transport by renal organic cation transporter hOCT2. Drug Metab Pharmacokinet. 2006, 21: 432-436. 10.2133/dmpk.21.432.PubMedView ArticleGoogle Scholar
- Eisner C, Faulhaber-Walter R, Wang Y, Leelahavanichkul A, Yuen PS, Mizel D, Star RA, Briggs JP, Levine M, Schnermann J: Major contribution of tubular secretion to creatinine clearance in mice. Kidney Int. 2010, 77: 519-526. 10.1038/ki.2009.501.PubMedPubMed CentralView ArticleGoogle Scholar
- Arendshorst WJ, Selkurt EE: Renal tubular mechanisms for creatinine secretion in the guinea pig. Am J Physiol. 1970, 218: 1661-1670.PubMedGoogle Scholar
- Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Endou H: Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002, 300: 918-924. 10.1124/jpet.300.3.918.PubMedView ArticleGoogle Scholar
- Genc G, Ozkaya O, Acikgoz Y, Yapici O, Bek K, Gulnar Sensoy S, Ozyurek E: Acute renal failure with acyclovir treatment in a child with leulemia. Drug Chem Toxicol. 2010, 33: 217-219. 10.3109/01480540903311076.PubMedView ArticleGoogle Scholar
- Schreiber R, Wolpin J, Koren G: Determinants of aciclovir-induced nephrotoxicity in children. Paediatr Drugs. 2008, 10: 135-139. 10.2165/00148581-200810020-00008.PubMedView ArticleGoogle Scholar
- Fauth C, Rossier B, Roch-Ramel F: Transport of tetraethylammonium by a kidney epithelial cell line (LLC-PK1). Am J Physiol. 1988, 254: F351-357.PubMedGoogle Scholar
- Saito H, Yamamoto M, Inui K, Hori R: Transcellular transport of organic cation across monolayers of kidney epithelial cell line LLC-PK1. Am J Physiol. 1992, 262: C59-66.PubMedGoogle Scholar
- Urakami Y, Kimura N, Okuda M, Masuda S, Katsura T, Inui K: Transcellular transport of creatinine in renal tubular epithelial cell line LLC-PK1. Drug Metab Pharmacokinet. 2005, 20: 200-205. 10.2133/dmpk.20.200.PubMedView ArticleGoogle Scholar
- Perantoni A, Berman JJ: Properties of Wilms' tumor line (TuWi) and pig kidney line (LLC-PK1) typical of normal kidney tubular epithelium. In Vitro. 1979, 15: 446-454. 10.1007/BF02618414.PubMedView ArticleGoogle Scholar
- Riddick DS: Drug biotransformation. Principles of Medical Pharmacology. Edited by: Kalant H, Roschlau WHE. 1998, New York: Oxford University Press, Inc, 38-54. 6Google Scholar
- Eaton DL, Klaassen CD: Principles of Toxicology. Casarett & Doull's Toxicology, the basic science of poisons. Edited by: Klaassen CD. 2001, New York: McGraw-Hill Companies, Inc, 11-34. 6Google Scholar
- Davila JC, Rodriguez RJ, Melchert RB, Acosta D: Predictive value of in vitro model systems in toxicology. Annu Rev Pharmacol Toxicol. 1998, 38: 63-96. 10.1146/annurev.pharmtox.38.1.63.PubMedView ArticleGoogle Scholar
- Grundemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H: Drug excretion mediated by a new prototype of polyspecific transporter. Nature. 1994, 372: 549-552. 10.1038/372549a0.PubMedView ArticleGoogle Scholar
- Andreev E, Koopman M, Arisz L: A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible?. J Intern Med. 1999, 246: 247-252. 10.1046/j.1365-2796.1999.00515.x.PubMedView ArticleGoogle Scholar
- Mersch-Sundermann V, Knasmuller S, Wu XJ, Darroudi F, Kassie F: Use of a human-derived liver cell line for the detection of cytoprotective, antigenotoxic and cogenotoxic agents. Toxicology. 2004, 198: 329-340. 10.1016/j.tox.2004.02.009.PubMedView ArticleGoogle Scholar
- NCBI Unigene. Organic cation transporter 1 (OCT1). [http://www.ncbi.nlm.nih.gov/UniGene/clust.cgi?ORG=Ssc%26CID=23507%26itool=HomoloGeneMainReport]
- NCBI Unigene. Solute carrier family 22 (organic cation transporter), member 2 (SLC22A2). [http://www.ncbi.nlm.nih.gov/UniGene/clust.cgi?UGID=454108%26TAXID=9823%26SEARCH=organic cation transporter 2]
- Dresser MJ, Leabman MK, Giacomini KM: Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J Pharm Sci. 2001, 90: 397-421. 10.1002/1520-6017(200104)90:4<397::AID-JPS1000>3.0.CO;2-D.PubMedView ArticleGoogle Scholar
- Grundemann D, Babin-Ebell J, Martel F, Ording N, Schmidt A, Schomig E: Primary structure and functional expression of the apical organic cation transporter from kidney epithelial LLC-PK1 cells. J Biol Chem. 1997, 272: 10408-10413. 10.1074/jbc.272.16.10408.PubMedView ArticleGoogle Scholar
- Zucco F, De Angelis I, Testai E, Stammati A: Toxicology investigations with cell culture systems: 20 years after. Toxicol In Vitro. 2004, 18: 153-163. 10.1016/S0887-2333(03)00147-4.PubMedView ArticleGoogle Scholar
- Hori R, Okamura M, Takayama A, Hirozane K, Takano M: Transport of organic anion in the OK kidney epithelial cell line. Am J Physiol. 1993, 264: F975-980.PubMedGoogle Scholar
- Mertens JJ, Weijnen JG, van Doorn WJ, Spenkelink B, Temmink JH, van Bladeren PJ: Differential toxicity as a result of apical and basolateral treatment of LLC-PK1 monolayers with S-(1,2,3,4,4-pentachlorobutadienyl)glutathione and N-acetyl-S-(1,2,3,4,4-pentachlorobutadienyl)-L-cysteine. Chem Biol Interact. 1988, 65: 283-293. 10.1016/0009-2797(88)90113-5.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.